Coloplast reshuffles ELT with new CPO and Wound unit interim lead
Coloplast has announced two changes to its Executive Leadership Team, effective from August and September 2026 respectively, as the Danish medtech group adjusts its senior structure ahead of what chief executive Gavin Wood has described as its next phase of growth.
Amanda Rajkumar will join the ELT as Chief People Officer from 1 September, bringing approximately 30 years of international human resources experience spanning the consumer and financial services sectors. Her most recent role was Executive Board Member for Human Resources at adidas, where she held global responsibility for people and culture. Before that she served as Chief Human Resource Officer for the Americas at BNP Paribas and held senior HR positions at JPMorgan Chase.
New CPO mandate
Rajkumar's stated mandate is to evolve Coloplast's people agenda to support its longer-term commercial ambitions, with an emphasis on leadership development, talent pipelines and succession planning. Wood said in the announcement that building "a winning culture" is "critical to our continued success" and welcomed Rajkumar's track record in large, globally distributed organisations.
The appointment of a dedicated Chief People Officer with a board-level background in non-healthcare sectors is a signal that Coloplast is treating its talent and culture infrastructure as a strategic priority rather than a purely operational function. Several medtech peers of comparable scale have made similar moves in recent years, hiring HR executives from outside the sector as they navigate workforce complexity tied to acquisitions and geographic expansion.
Wound and Tissue Repair transition
Separately, Fertram Sigurjonsson, the founder of Kerecis, will step down from his role as Executive Vice President of Wound and Tissue Repair and move into a newly created position as Chief Innovation and Technology Advisor to the CEO, effective immediately. In that role he will focus on Coloplast's biologics and advanced wound care innovation agenda, and on what the company describes as emerging technologies within wound healing.
Sigurjonsson co-founded Kerecis, the Icelandic company known for its fish-skin derived wound-care biologics, before it was acquired by Coloplast. His transition out of the operational ELT seat preserves his expertise in the organisation while freeing the divisional leadership structure for a reset. Wood will lead the Wound and Tissue Repair business on an interim basis while a longer-term arrangement is determined, though Coloplast has not indicated a timeline for appointing a permanent successor.
The Wound and Tissue Repair segment sits in a competitive market that includes established players in collagen-based and synthetic advanced wound dressings, as well as a growing cohort of regenerative medicine companies seeking regulatory clearance for biological and bioengineered skin substitutes. Coloplast acquired Kerecis in 2022 and has since positioned the fish-derived acellular fish-skin matrix as a differentiator within that landscape; sustaining the innovation momentum from that platform while integrating it more deeply into the broader group will be a key test of the new structure.
Coloplast, listed on Nasdaq Copenhagen, operates across ostomy care, continence care, voice and respiratory care, wound and tissue repair, and interventional urology. The company does not report divisional revenue separately in its standard results disclosures, which limits external scrutiny of the Wound and Tissue Repair unit's individual performance trajectory.